Analysts are on the Bearish side about Walgreens Boots Alliance, Inc. (NASDAQ:WBA) this week.

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Logo

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Ratings Coverage

Among 5 analysts covering Walgreens Boots Alliance (NASDAQ:WBA), 0 have Buy rating, 1 Sell and 4 Hold. Therefore 0 are positive. Walgreens Boots Alliance has $7400 highest and $49 lowest target. $60.17’s average target is 7.47% above currents $55.99 stock price. Walgreens Boots Alliance had 11 analyst reports since March 18, 2019 according to SRatingsIntel. The firm has “Equal-Weight” rating given on Wednesday, April 3 by Morgan Stanley. The stock of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has “Equal-Weight” rating given on Wednesday, April 3 by Barclays Capital. The company was downgraded on Wednesday, April 3 by Loop Capital. UBS maintained Walgreens Boots Alliance, Inc. (NASDAQ:WBA) on Wednesday, April 3 with “Sell” rating. The stock of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) earned “Equal-Weight” rating by Morgan Stanley on Friday, August 23. The stock of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has “Neutral” rating given on Wednesday, April 3 by Citigroup. Below is a list of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) latest ratings and price target changes.

23/08/2019 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $61.0000 New Target: $58.0000 Maintain
28/06/2019 Broker: Inc. – Common Stock Rating: Jp Morgan New Target: $74.0000 73.0000
03/06/2019 Broker: Inc. – Common Stock Rating: Bank Of America New Target: $53.0000 51.0000
30/05/2019 Broker: BidaskScore Rating: Sell Upgrade
13/04/2019 Broker: BidaskScore Rating: Sell Downgrade
03/04/2019 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $67 New Target: $61 Maintain
03/04/2019 Broker: Citigroup Old Rating: Neutral New Rating: Neutral Old Target: $76 New Target: $60 Maintain
03/04/2019 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $78 New Target: $60 Maintain
03/04/2019 Broker: UBS Old Rating: Sell New Rating: Sell Old Target: $60 New Target: $49 Maintain
03/04/2019 Broker: Loop Capital Old Rating: Buy New Rating: Hold Old Target: $77 New Target: $60 Downgrade

The stock increased 0.77% or $0.43 during the last trading session, reaching $55.99. About 3.26M shares traded. Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has declined 21.21% since September 13, 2018 and is downtrending. It has underperformed by 21.21% the S&P500.

Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and wellbeing company. The company has market cap of $50.57 billion. It operates through three divisions: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. It has a 10.96 P/E ratio. The Retail Pharmacy USA segment sells prescription drugs and an assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its retail drugstores and convenient care clinics.

More notable recent Walgreens Boots Alliance, Inc. (NASDAQ:WBA) news were published by: Nasdaq.com which released: “Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know – Nasdaq” on June 12, 2019, also Nasdaq.com with their article: “Walgreens (WBA) 2nd Quarter Earnings: What to Expect – Nasdaq” published on April 01, 2019, Businesswire.com published: “Walgreens and Vitamin Angels Reach 200 Million Women and Children with Life-Changing Vitamins – Business Wire” on September 10, 2019. More interesting news about Walgreens Boots Alliance, Inc. (NASDAQ:WBA) were released by: Nasdaq.com and their article: “Market Close Report: NASDAQ Composite index closes at 7,962.88 down -10.51 points – Nasdaq” published on August 30, 2019 as well as Nasdaq.com‘s news article titled: “Earnings Preview: Walgreens Boots Alliance (WBA) Q2 Earnings Expected to Decline – Nasdaq” with publication date: March 26, 2019.

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.